Well, I didn't intend to engage in a discussion about accumulated losses and the nature of their assets, whether tangible or intangible. I was merely countering any assumption that they could not fund their current clinical trials with cash on hand. Again, beside the point, but accumulated losses have some benefit, and as you know they have no relationship to current cash on hand, burn rate, or liabilities.
Market Data 
Markets 
AI
